Overview
ANeuroTech is developing its late stage Phase III drug ANT01, an once-daily orally-administered small molecule targeting Partial Responsive Depression (PRD) and subjective cognitive decline. ANT01 acts as a combined High Selective Serotonin 2A/Dopamine 4 receptor blocker. The company was founded by Dr. Erik Buntinx, a psychiatrist with over 3 decades of experience in clinical neuroscience drug development.
Key people
In the news
- Heading to Boston to meet one-to-one or at dinner multiple Top 20 Pharma Partners as accepted. ANIMA Research ANeuroTech
- Heading to Boston to meet one-to-one or at dinner multiple Top 20 Pharma Partners as accepted. ANIMA Research ANeuroTech
Alumni 1 went on to found or lead
Erik BuntinxFounding CEO & Inventor→Founding CEO at ANIMA Clinical
Something wrong or missing? Send an update. Fixed within 24 hours.